BRAIN Biotech AG (XTER:BNN) Cash-to-Debt : 2.42 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BRAIN Biotech AG's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.42.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BRAIN Biotech AG could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for BRAIN Biotech AG's Cash-to-Debt or its related term are showing as below:

XTER:BNN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.16 Med: No Debt Max: No Debt
Current: 2.42

During the past 9 years, BRAIN Biotech AG's highest Cash to Debt Ratio was No Debt. The lowest was 1.16. And the median was No Debt.

XTER:BNN's Cash-to-Debt is ranked better than
70.07% of 1547 companies
in the Chemicals industry
Industry Median: 0.74 vs XTER:BNN: 2.42

BRAIN Biotech AG Cash-to-Debt Historical Data

The historical data trend for BRAIN Biotech AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BRAIN Biotech AG Cash-to-Debt Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

9.33

2.93

1.16

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	N/A	1.16	N/A	2.42

Competitive Comparison of BRAIN Biotech AG's Cash-to-Debt

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG's Cash-to-Debt Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Cash-to-Debt falls into.

BRAIN Biotech AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BRAIN Biotech AG's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.407	/	(4.659	+	0)
	=	1.16

BRAIN Biotech AG's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	10.352	/	(0	+	4.276)
	=	2.42

BRAIN Biotech AG (XTER:BNN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BRAIN Biotech AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines